Balance Sheet (Annual)

LANC / Lancaster Colony Corp. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2012 2013 2014 2015 2016 2017
Assets
  Cash And Cash Equivalents At Carrying Value 191,636 123,386 211,539 182,202 118,080 143,104
  Assets Current
  Receivables Net Current 73,326 70,398 57,808 62,437 66,006 69,922
  Inventory Net
    Inventory Raw Materials Net Of Reserves 36,005 35,012 28,069 30,655 26,153 28,447
    Inventory Finished Goods And Work In Process Net Of Reserves 73,699 74,139 - - - -
    Inventory Finished Goods Net Of Reserves - - 46,447 47,244 49,944 47,929
    Inventory Net 109,704 109,151 74,516 77,899 76,097 76,376
    Deferred Income Taxes And Other Assets Current 17,073 23,123 23,428 20,460 - -
    Other Assets Current - - - - 7,644 11,744
    Assets Of Disposal Group Including Discontinued Operation Current - - 0 - - -
    Assets Current 391,739 326,058 367,291 342,998 267,827 301,146
  Property Plant And Equipment Net
    Land Buildings And Improvements 140,337 144,206 107,690 113,844 116,858 124,673
    Machinery And Equipment Gross 276,951 289,051 238,791 253,143 263,336 272,582
    Property Plant And Equipment Gross 417,288 433,257 346,481 366,987 380,194 397,255
    Accumulated Depreciation Depletion And Amortization Property Plant And Equipment 233,158 243,562 177,807 194,676 210,599 216,584
    Property Plant And Equipment Net 184,130 189,695 168,674 172,311 169,595 180,671
    Other Assets Noncurrent
      Goodwill 89,840 89,840 89,840 143,788 143,788 168,030
      Finite Lived Intangible Assets Net 7,267 6,322 5,376 47,771 44,866 60,162
      Other Assets Noncurrent 9,659 8,049 7,449 8,076 8,656 6,396
      Assets Of Disposal Group Including Discontinued Operation Noncurrent - - 0 - - -
  Assets 682,635 619,964 638,630 714,944 634,732 716,405
Liabilities And Stockholders Equity
  Liabilities Current
    Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities Current - - 0 - - -
    Commitments And Contingencies - - - - - -
  Accounts Payable Current 40,708 41,890 37,907 38,823 39,931 41,353
  Accrued Liabilities Current 31,963 35,287 31,165 35,821 33,072 35,270
  Liabilities Current 72,671 77,177 69,072 74,644 73,003 76,623
  Other Liabilities Noncurrent 31,627 23,291 22,208 23,654 26,698 38,598
  Deferred Tax Liabilities Noncurrent 14,070 18,274 18,753 35,728 21,433 25,207
  Equity
    Preferred Stock Value Outstanding - - - - - -
    Common Stock Value 100,015 102,622 104,789 107,767 110,677 115,174
    Retained Earnings Accumulated Deficit 1,208,027 1,139,213 1,167,211 1,219,119 1,150,337 1,206,671
    Accumulated Other Comprehensive Income Loss Defined Benefit Pension And Other Postretirement Plans Net Of Tax 12,162 8,391 8,061 10,057 11,350 8,936
    Treasury Stock Value 731,613 732,222 735,342 735,911 736,066 736,932
    Stockholders Equity 564,267 501,222 528,597 580,918 513,598 575,977
    Liabilities And Stockholders Equity 682,635 619,964 638,630 714,944 634,732 716,405

Peers - Canned, Frozen, And Preserved Fruits, Vegetables, and Food Specialties (203)

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 513847103